#Germany #Hamburg #ctDNA #Haystack MRD #MVZ HPH

MVZ HPH Introduces a Revolutionary ctDNA Blood Test for Cancer Monitoring

In a significant advancement for cancer diagnostics, the MVZ HPH Institute for Pathology and Hematopathology GmbH in Hamburg, Germany, has launched the HPH MRD test, harnessing the cutting-edge Haystack MRD® technology. This tumor-informed circulating-tumor DNA (ctDNA) blood test is designed to detect minimal residual disease (MRD) in patients with solid tumors. With the ability to identify incredibly low levels of ctDNA, this test offers a new avenue for monitoring cancer recurrence and aiding treatment decisions.

A Breakthrough in Cancer Studies

The HPH MRD test is a groundbreaking advancement in the realm of cancer treatment monitoring. Unlike traditional methods, which can miss small amounts of residual cancer cells post-treatment, this test provides clinicians with a tool for remarkably early detection of potential disease recurrence. Utilizing Haystack's proprietary technology—developed by Quest Diagnostics—this test's exceptional sensitivity allows for a more accurate assessment of patient health throughout their treatment journey.

By employing whole-genome sequencing, HPH MRD analyzes tumor tissue to create personalized testing panels for patients. This bespoke approach gives healthcare professionals clearer insights into individual ctDNA levels, enabling tailored strategies in cancer management. Prof. Markus Tiemann, CEO of MVZ HPH, highlighted the importance of this development, stating, "By licensing Haystack's groundbreaking MRD technology, we can now provide our patients with access to vital testing that was previously only available in other countries, ensuring quicker results and better support in their treatment decisions."

Improved Access to Cutting-Edge Technology

One of the most critical advantages this test offers is its local availability within Germany. Historically, patients in Europe had limited access to these advanced MRD testing technologies, often requiring overseas shipping of samples for analysis. Now, with HPH’s commitment to maintaining all testing procedures and data within their Hamburg laboratories, clinicians can expect a fast turnaround, promoting timely and informed clinical responses that can significantly impact patient outcomes.

The ability to quickly assess ctDNA levels in real time means that doctors can make confident treatment decisions based on the most current data available, enhancing the standard of care for cancer patients across Europe. This is an essential leap forward in the field of oncology, where timely interventions can drastically improve survival rates.

Empowering Decision Making with ctDNA Testing

The introduction of ctDNA MRD testing into routine cancer care represents a pivotal shift in how oncologists approach patient management. By identifying tumor-derived DNA fragments circulating in the bloodstream, medical professionals can gather molecular evidence of disease that standard imaging processes might overlook. This enhanced capability allows for the monitoring of patients at risk of recurrence after surgery, chemotherapy, or other treatments.

Dan Edelstein, Vice President of General Manager at Haystack Oncology, emphasized the significance of this development for European patients and doctors: "Patients and physicians in Europe have lacked convenient access to the most sensitive MRD technologies, with samples often needing to be shipped internationally. Our partnership with HPH marks a vital step toward integrating next-generation MRD testing into routine cancer care beyond the U.S."

Moving Forward with Confidence

Overall, the launch of the HPH MRD test by MVZ HPH Institute signifies an essential milestone in the fight against cancer. By putting this advanced testing solution in the hands of local healthcare providers, patients can receive timely diagnostics and evaluations that are crucial in managing their health effectively. As technology continues to evolve, the medical community eagerly anticipates further innovations that will enhance cancer treatment and ultimately save lives.

For more information about the HPH MRD test, you can contact MVZ HPH at email protected] or visit [www.haematopathologie-hamburg.de.